InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(7-8), С. 46 - 57
Опубликована: Июль 1, 2024
International Journal of Hyperthermia, Год журнала: 2025, Номер 42(1)
Опубликована: Янв. 12, 2025
This review was written to be included in the Special Collection 'Therapy Ultrasound: Medicine's Swiss Army Knife?' The purpose of this is provide basic presentation and interpretation fundamentals hyperthermia biology, as it pertains uses therapeutic ultrasound. are presented but setting a translational view toward future. Subjects that require future research development highlighted. effects time temperature dependent. Because intra-tumoral temperatures non-uniform tumors, one has account for differential biologic different parts tumor occur simultaneously during after hyperthermia.
Язык: Английский
Процитировано
0
Molecular Therapy — Nucleic Acids, Год журнала: 2025, Номер 36(2), С. 102500 - 102500
Опубликована: Март 5, 2025
Chemoradiotherapy is the standard of care for many locally advanced cancers, including cervical and head neck but patients cannot tolerate chemotherapy. Clinical trials have shown that radiotherapy combined with hyperthermia (thermoradiotherapy) may be equally effective, yet it yields a suboptimal overall survival patients, emphasizing need improvement. MicroRNAs (miRNAs), short non-coding RNA sequences, are often dysregulated in cancer exhibit significant potential as radiosensitizers by targeting genes associated DNA damage response. In this study, high-throughput miRNA screening four cell lines identified 55 miRNAs sensitizing potential, 18 validated across 10 additional (6 4 neck). Functional studies 6 miRNAs, miR-16, miR-27a, miR-181c, miR-221, miR-224, miR-1293, showed they reduced repair downregulating ATM, DNA-PKcs, Ku70/80, RAD51. Additionally, differential expression miR-224 treatment-sensitive versus treatment-resistant indicated their predictive biomarker treatment response patients. Conclusively, study has promising development sensitizers thermoradiotherapy provide biomarkers predicting cancers.
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2024, Номер 14
Опубликована: Май 30, 2024
Despite a comparatively favorable prognosis relative to other malignancies, breast cancer continues significantly impact women’s health globally, partly due its high incidence rate. A critical factor in treatment failure is radiation resistance – the capacity of tumor cells withstand doses ionizing radiation. Advancements understanding cellular and molecular mechanisms underlying radioresistance, coupled with enhanced characterization radioresistant cell clones, are paving way for development novel modalities that hold potential future clinical application. In context combating radioresistance cancer, targets interest include long non-coding RNAs (lncRNAs), micro (miRNAs), their associated signaling pathways, along signal transduction routes amenable pharmacological intervention. Furthermore, technical, methodological innovations, such as integration hyperthermia or nanoparticles radiotherapy, have enhance responses patients cancer. This review endeavors provide comprehensive survey current scientific landscape, focusing on therapeutic advancements specifically addressing
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2024, Номер 16(23), С. 3916 - 3916
Опубликована: Ноя. 22, 2024
The conventional radiation treatment of cancer patients has typically involved a large number daily treatments with relatively low doses radiation. However, improved technology now resulted in the increased use fewer fractions at high dose per fraction. This latter approach is often referred to as hypofractionated irradiation. While kills tumor cells through production DNA damage, higher fraction have been suggested also kill via induction vascular damage. Such effects will increase level adverse microenvironmental conditions, such hypoxia and acidity, that already exist tumors. Cells existing these conditions are resistant but actually sensitive hyperthermia (heating 40-45 °C) treatment. suggests combination heat may be viable approach. there preliminary pre-clinical even clinical studies investigating this option, no data on optimal application for greatest therapeutic benefit. In critical review, we present rationale combining discuss what done should establish an effective therapy option.
Язык: Английский
Процитировано
1
Medical Physics, Год журнала: 2024, Номер 51(10), С. 7606 - 7618
Опубликована: Июнь 25, 2024
Abstract Background Magnetic hyperthermia (MHT) has emerged as a promising therapeutic approach in the field of radiation oncology due to its superior precision controlling temperature and managing heating area compared conventional hyperthermia. Recent studies have proposed solutions address clinical safety concerns associated with MHT, which arise from use highly concentrated magnetic nanoparticles strong needed induce hyperthermic effects. Despite these efforts, challenges remain quantifying outcomes developing treatment plan systems for combining MHT therapy (RT). Purpose This study aims quantitatively measure effect, including dose enhancement (RDE) hyperthermia‐radiation combined (MHRT), using equivalent (EQD) estimation method. Methods To conduct EQD MHRT, we effects between (HTRT) MHRT human prostate cancer cell lines, PC3 LNCaP. We adopted clonogenic assay validate RDE radiosensitizing effect induced by MHT. The data on survival fractions were analyzed both linear‐quadradic model Arrhenius estimate biological parameters describing lines through maximum likelihood estimation. Based parameters, new fraction was suggested MHRT. Results newly designed effectively captures variations thermal ( R 2 > 0.95), suitability confirmed normality test residuals. appropriately describes up 10 Gy cells 8 LNCaP under RT‐only conditions. Furthermore, defined parameter r , calculated 29% 23% cells. this 9.47 4.71 when given 30 min. Compared HTRT showed 26% increase 20% Conclusions changes adequately represents actual values residual analysis. Newly shows potential quantitative comparisons optimizing cancer.
Язык: Английский
Процитировано
0
InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(7-8), С. 46 - 57
Опубликована: Июль 1, 2024
Процитировано
0